Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis

AbstractThe mortality effects and risk –benefit profile of low dose rivaroxaban (2.5 mg twice daily) in patients with coronary heart disease are not completely understood. Five randomized controlled trials (26,110 patients) were selected using PubMed and Cochrane library till April 2019. The background antiplatelet therapy was aspirin in 3 trials, P2Y12 inhibitor in 1 trial, and in 1 trial 65% patients received aspirin and 35% were on dual antiplatelet therapy (DAPT). The outcomes of interest were cardiovascular mortality, all-cause mortality, myocardial infarction (MI), stroke and major bleeding events. Random effects hazard ra tios (HR) with 95% confidence intervals (CI) were calculated. Low dose rivaroxaban did not reduce the risk of cardiovascular mortality (HR 0.90, 95% CI 0.73–1.11, P = 0.34) or all-cause mortality (HR 0.91, 95% CI 0.74–1.12, P = 0.38) compared with control. However, low dose rivaroxaban w as associated with reduction in MI (HR 0.85, 95% CI 0.73–0.99, P = 0.04), and stroke (HR 0.59, 95%CI 0.48–0.73, P 
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research

Related Links:

Publication date: Available online 10 July 2020Source: Clinica Chimica ActaAuthor(s): Elizabeth Fragopoulou, Smaragdi Antonopoulou
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
CONCLUSION: The preventive strategy is fundamental, since the therapy is complex with poorly validated effectiveness. PMID: 32645129 [PubMed - as supplied by publisher]
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
CONCLUSIONS: Extracting from the group of genes related to coronary atherosclerosis and cardiac failure: MMP-9, TGF-β1 and TIMP-1 differentiating patients with heart failure on the basis of myocardial ischemia in varying degrees of severity from healthy people may indicate their significant contribution to disease development. Also increased expression of the metalloproteinase gene 9 (MMP-9) with a simultaneous decrease in the expression of its tissue inhibitor 1 (TIMP-1) in the studied group of patients with ischemic heart failure differing in left ventricular ejection fraction (LVEF) makes them the markers of progre...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Authors: Buono A, Ielasi A, Colombo A Abstract Bioresorbable scaffolds (BRS) have been introduced in the last decade in percutaneous coronary interventions. Despite several advantages being postulated, the negative results from the mid-term follow-up of the Absorb trials have tempered enthusiasm for these innovative devices. The Absorb scaffold was associated with higher rates of target-lesion failure and scaffold thrombosis when compared to current metallic stents, and for this reason was withdrawn from the market. This failure has to be considered multifactorial, involving technical and technological aspects. Con...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Authors: Stepien K, Furczynska P, Zalewska M, Nowak K, Wlodarczyk A, Owsianka I, Skorek P, Zalewski J, Nessler J Abstract BACKGROUND: Recently heart failure (HF) has been found to be a new dementia risk factor, nevertheless their relations in patients following HF decompensation remain unknown. We sought to investigate whether a screening diagnosis for dementia (SDD) in this high-risk population may predict unfavorable long-term clinical outcomes. METHODS: 142 patients following HF decompensation requiring hospitalization were enrolled. Within a median time of 55 months all patients were screened for dementia w...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
We describe a young man with antiphospholipid syndrome, who developed overt pulmonary thromboembolism due to an isolated thrombus in the left renal vein. Complicating antiphospholipid syndrome might trigger acute pulmonary thromboembolism (APTE) in patients with NCS. To the best of our knowledge, this is the first report of APTE arising due to isolated left renal vein thrombosis in patients with NCS. PMID: 32641637 [PubMed - as supplied by publisher]
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Authors: Su W, Wang M, Zhu J, Li W, Ding X, Chen H, Li HW, Zhao XQ Abstract Increased body mass index (BMI) is a well-established risk factor for cardiovascular disease; however, patients with elevated BMI, in comparison to those with low BMI, seem to have better survival, a phenomenon reported as "obesity paradox," which remains controversial. We investigated the effect of BMI on cardiac mortality post acute myocardial infarction (AMI).In this analysis, 3562 AMI patients were included and classified into four groups based on BMI values. The primary endpoint was cardiac death. Compared to normoweight grou...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Exertional heat stroke (EHS) and malignant hyperthermia (MH) are life-threatening conditions, triggered by different environmental stimuli that share several clinical symptoms and pathophysiological features. EHS manifests during physical activity normally...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Environmental Issues, Climate, Geophysics Source Type: news
Condition:   Von Willebrand Diseases Intervention:   Sponsor:   University Hospital, Lille Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Coronary Heart Disease | Databases & Libraries | Heart | Heart Attack | Heart Disease | Hematology | Stroke | Thrombosis